Journal
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 4, Issue 10, Pages 1670-1676Publisher
AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.04140609
Keywords
-
Categories
Funding
- National Institutes of Health [R01DK074661, R21DK077331]
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK074661, R21DK077331] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The idea of individualizing therapies to obtain optimal clinical results is not new but has only recently been applied to kidney diseases. Nonetheless, kidney disorders present a variety of opportunities to personalize medicine. Here, the heterogeneity of kidney disorders is reviewed to provide a rationale for pursuing personalized medicine. Data on adjusting therapy on the basis of pharmacogenetics/genomics and pharmacodynamics are summarized to demonstrate where the field is, and biomarker studies that reflect the future of personalized medicine are discussed. The goal of this review is to demonstrate that we can personalize therapy for kidney diseases but that considerable investment in new research will be required for personalized medicine to be routinely used in nephrology clinics. Clin J Am Soc Nephrol 4: 1670-1676, 2009. doi: 10.2215/CJN.04140609
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available